Imago BioSciences, Inc. financial data

Location
303 Twin Dolphin Drive, 6 Th Floor, Redwood City, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2022 - Nov 9, 2022

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.76K %
Return On Equity -31.9 % +100%
Return On Assets -30.1 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 33.8M shares +0.88%
Common Stock, Shares, Outstanding 33.8M shares +1.07%
Common Stock, Value, Issued 3K USD 0%
Weighted Average Number of Shares Outstanding, Basic 33.8M shares +26.6%
Weighted Average Number of Shares Outstanding, Diluted 33.8M shares +26.6%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 47.3M USD +55%
General and Administrative Expense 15.5M USD +34.7%
Operating Income (Loss) -62.9M USD -49.7%
Nonoperating Income (Expense) 1.26M USD +1444%
Income Tax Expense (Benefit) 2K USD
Net Income (Loss) Attributable to Parent -61.6M USD -86%
Earnings Per Share, Basic -0.5 USD/shares -13.6%
Earnings Per Share, Diluted -0.5 USD/shares -13.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 7.29M USD -91.4%
Cash, Cash Equivalents, and Short-term Investments 178M USD -22.6%
Assets, Current 182M USD -22.4%
Property, Plant and Equipment, Net 2K USD -71.4%
Other Assets, Noncurrent 4.42M USD +65.4%
Assets 186M USD -21.4%
Accounts Payable, Current 3.9M USD +105%
Employee-related Liabilities, Current 2.47M USD +56%
Accrued Liabilities, Current 3.12M USD -55.5%
Liabilities, Current 13.8M USD +55.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax -816K USD -5200%
Retained Earnings (Accumulated Deficit) -160M USD -62.9%
Stockholders' Equity Attributable to Parent 173M USD -24.4%
Liabilities and Equity 186M USD -21.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -11.5M USD -63.3%
Net Cash Provided by (Used in) Financing Activities 454K USD
Net Cash Provided by (Used in) Investing Activities 8.1M USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 33.8M shares +1.07%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.97M USD +71.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -62.5M USD -43.6%
Depreciation, Depletion and Amortization 1K USD -66.7%
Share-based Payment Arrangement, Expense 4.57M USD +301%